Premium
Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study
Author(s) -
AbdElsalam Sherief,
Noor Rasha A.,
Badawi Rehab,
Khalaf Mai,
Esmail Eslam S.,
Soliman Shaimaa,
Abd El Ghafar Mohamed S.,
Elbahnasawy Mohamed,
Moustafa Ehab F.,
Hassany Sahar M.,
Medhat Mohammed A.,
Ramadan Haidi KaramAllah,
Eldeen Maii A. S.,
Alboraie Mohamed,
Cordie Ahmed,
Esmat Gamal
Publication year - 2021
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.27122
Subject(s) - ivermectin , medicine , randomized controlled trial , mechanical ventilation , covid-19 , surgery , anesthesia , disease , veterinary medicine , infectious disease (medical specialty)
Researchers around the world are working at record speed to find the best ways to treat and prevent coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID‐19 infected patients. This was a randomized open‐label controlled study that included 164 patients with COVID‐19. Patients were randomized into two groups where Group 1 (Ivermectin group) included patients who received ivermectin 12 mg once daily for 3 days with standard care and Group 2 (control group) included patients who received standard protocol of treatment alone for 14 days. The main outcomes were mortality, the length of hospital stay, and the need for mechanical ventilation. All patients were followed up for 1 month. Overall, 82 individuals were randomized to receive ivermectin plus standard of care and 82 to receive standard of care alone. Patients in the ivermectin group had a shorter length of hospital stay (8.82 ± 4.94 days) than the control group (10.97 ± 5.28 days), but this was not statistically significant ( p = 0.085). Three patients (3.7%) in each group required mechanical ventilation ( p = 1.00). The death rate was three patients in the ivermectin group (3.7%) versus four patients (4.9%) in the control group without any significant difference between the two groups ( p = 1.00). Although there was no statistically significant difference in any endpoints by ivermectin doses (12 mg/day for 3 days); there was an observed trend to reducing hospital stay in the ivermectin‐treated group.